AFAP1-AS1: a Rising Star among Oncogenic Long Non-Coding RNAs

Fang Xiong,Kunjie Zhu,Su Deng,Hongbin Huang,Liting Yang,Zhaojian Gong,Lei Shi,Yi He,Yanyan Tang,Qianjin Liao,Jianjun Yu,Xiaoling Li,Yong Li,Guiyuan Li,Zhaoyang Zeng,Wei Xiong,Shanshan Zhang,Can Guo
DOI: https://doi.org/10.1007/s11427-020-1874-6
2021-01-01
Science China Life Sciences
Abstract:Long non-coding RNAs (lncRNAs) have become a hotspot in biomedical research. This interest reflects their extensive involvement in the regulation of the expression of other genes, and their influence on the occurrence and development of a variety of human diseases. Actin filament associated protein 1-Antisense RNA 1(AFAP1-AS1) is a recently discovered oncogenic lncRNA. It is highly expressed in a variety of solid tumors, and regulates the expression of downstream genes and signaling pathways through adsorption and competing microRNAs, or by the direct binding to other proteins. Ultimately, AFAP1-AS1 promotes proliferation, chemotherapy resistance, and resistance to apoptosis, maintains stemness, and enhances invasion and migration of tumor cells. This paper summarizes the research concerning AFAP1-AS1 in malignant tumors, including the clinical application prospects of AFAP1-AS1 as a potential molecular marker and therapeutic target of malignant tumors. We also discuss the limitations in the knowledge of AFAP1-AS1 and directions of further research. AFAP1-AS1 is expected to provide an example for studies of other lncRNA molecules.
What problem does this paper attempt to address?